DE3107100A1 - Azaprostacycline, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung - Google Patents

Azaprostacycline, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung

Info

Publication number
DE3107100A1
DE3107100A1 DE19813107100 DE3107100A DE3107100A1 DE 3107100 A1 DE3107100 A1 DE 3107100A1 DE 19813107100 DE19813107100 DE 19813107100 DE 3107100 A DE3107100 A DE 3107100A DE 3107100 A1 DE3107100 A1 DE 3107100A1
Authority
DE
Germany
Prior art keywords
solution
alkyl
acid
hydrogen
carbon atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
DE19813107100
Other languages
German (de)
English (en)
Inventor
Jorge Dr. Casals-Stenzel
Ekkehard Dr. Schillinger
Norbert Dr. Schwarz
Werner Dr. Skuballa
Michael Harold Dr. 1000 Berlin Town
Helmut Prof. Dr. Vorbrüggen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Priority to DE19813107100 priority Critical patent/DE3107100A1/de
Priority to AU80388/82A priority patent/AU8038882A/en
Priority to JP57023695A priority patent/JPS57176960A/ja
Priority to CS821172A priority patent/CS228916B2/cs
Priority to ES509738A priority patent/ES8301914A1/es
Priority to IL65055A priority patent/IL65055A0/xx
Priority to AT82730015T priority patent/ATE36152T1/de
Priority to CA000396656A priority patent/CA1205468A/en
Priority to HU82519A priority patent/HU187649B/hu
Priority to EP82730015A priority patent/EP0059158B1/de
Priority to DK72782A priority patent/DK72782A/da
Priority to DE8282730015T priority patent/DE3278854D1/de
Priority to IE355/82A priority patent/IE54097B1/en
Priority to US06/350,674 priority patent/US4446147A/en
Publication of DE3107100A1 publication Critical patent/DE3107100A1/de
Priority to US06/591,719 priority patent/US4567195A/en
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C07D307/935Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0041Analogues having the carboxyl group in the side-chains replaced by other functional groups containing nitrogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/03Monocarboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13Dicarboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/26Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing rings other than six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40Esters thereof
    • C07F9/4003Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4015Esters of acyclic unsaturated acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40Esters thereof
    • C07F9/4003Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4018Esters of cycloaliphatic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE19813107100 1981-02-20 1981-02-20 Azaprostacycline, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung Ceased DE3107100A1 (de)

Priority Applications (15)

Application Number Priority Date Filing Date Title
DE19813107100 DE3107100A1 (de) 1981-02-20 1981-02-20 Azaprostacycline, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
AU80388/82A AU8038882A (en) 1981-02-20 1982-02-11 Azaprostacyclins
JP57023695A JPS57176960A (en) 1981-02-20 1982-02-18 Azaprostacycline, manufacture and medicine containing same
CA000396656A CA1205468A (en) 1981-02-20 1982-02-19 Azaprostacyclins, process for their manufacture and their pharmaceutical use
DK72782A DK72782A (da) 1981-02-20 1982-02-19 Azaprostacykliner,fremgangsmaade til deres fremstilling og deres fremstilling og deres farmaceutiske anvendelse
IL65055A IL65055A0 (en) 1981-02-20 1982-02-19 Azaprostacyclins,process for their manufacture and pharmaceutical preparations containing them
AT82730015T ATE36152T1 (de) 1981-02-20 1982-02-19 Azaprostacycline, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung.
CS821172A CS228916B2 (en) 1981-02-20 1982-02-19 Method of preparing new derivatives of 9 alpha,6-nitril
HU82519A HU187649B (en) 1981-02-20 1982-02-19 Process for preparing azaprostacyclin derivatives and pharmaceutical compositions containing such compounds as active substances
EP82730015A EP0059158B1 (de) 1981-02-20 1982-02-19 Azaprostacycline, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
ES509738A ES8301914A1 (es) 1981-02-20 1982-02-19 "procedimiento para la preparacion de azaprostaciclinas".
DE8282730015T DE3278854D1 (en) 1981-02-20 1982-02-19 Aza prostacyclins, their preparation and therapeutic applications
IE355/82A IE54097B1 (en) 1981-02-20 1982-02-22 Azaprostacyclins, process for their manufacture and their pharmaceutical use
US06/350,674 US4446147A (en) 1981-02-20 1982-02-22 Azaprostacyclins, their preparation and pharmaceutical use
US06/591,719 US4567195A (en) 1981-02-20 1984-03-21 Azaprostacyclins, their preparation and pharmaceutical use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19813107100 DE3107100A1 (de) 1981-02-20 1981-02-20 Azaprostacycline, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung

Publications (1)

Publication Number Publication Date
DE3107100A1 true DE3107100A1 (de) 1982-09-09

Family

ID=6125738

Family Applications (2)

Application Number Title Priority Date Filing Date
DE19813107100 Ceased DE3107100A1 (de) 1981-02-20 1981-02-20 Azaprostacycline, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
DE8282730015T Expired DE3278854D1 (en) 1981-02-20 1982-02-19 Aza prostacyclins, their preparation and therapeutic applications

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE8282730015T Expired DE3278854D1 (en) 1981-02-20 1982-02-19 Aza prostacyclins, their preparation and therapeutic applications

Country Status (13)

Country Link
US (2) US4446147A (cg-RX-API-DMAC10.html)
EP (1) EP0059158B1 (cg-RX-API-DMAC10.html)
JP (1) JPS57176960A (cg-RX-API-DMAC10.html)
AT (1) ATE36152T1 (cg-RX-API-DMAC10.html)
AU (1) AU8038882A (cg-RX-API-DMAC10.html)
CA (1) CA1205468A (cg-RX-API-DMAC10.html)
CS (1) CS228916B2 (cg-RX-API-DMAC10.html)
DE (2) DE3107100A1 (cg-RX-API-DMAC10.html)
DK (1) DK72782A (cg-RX-API-DMAC10.html)
ES (1) ES8301914A1 (cg-RX-API-DMAC10.html)
HU (1) HU187649B (cg-RX-API-DMAC10.html)
IE (1) IE54097B1 (cg-RX-API-DMAC10.html)
IL (1) IL65055A0 (cg-RX-API-DMAC10.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL76612A (en) * 1984-10-09 1990-01-18 Syntex Inc Intermediates for preparing 16-phenoxy-prostatrienoic acid derivatives and their preparation
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
IL156585A0 (en) * 2001-01-26 2004-01-04 Schering Corp Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
MXPA03006727A (es) * 2001-01-26 2003-10-24 Schering Corp Combinaciones de acido nicotinico y derivados del mismo con inhibidor(es) de la absorcion de los esteroles, y tratamiento para indicaciones vasculares.
EP1363668B1 (en) * 2001-01-26 2007-08-15 Schering Corporation Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
MEP27808A (en) * 2001-01-26 2010-10-10 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US20060287254A1 (en) * 2001-01-26 2006-12-21 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
JP2004517920A (ja) * 2001-01-26 2004-06-17 シェーリング コーポレイション 血管状態を治療するためのステロール吸収阻害剤と血液調整剤との組合せ
US7071181B2 (en) * 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
ATE331512T1 (de) * 2001-01-26 2006-07-15 Schering Corp Verwendung azetidinone-substituierter verbindungen zur behandlung der sitosterolhämie
AR038956A1 (es) * 2001-05-25 2005-02-02 Schering Corp Uso de un compuesto que regula la produccion o niveles de peptidos beta amiloides para la manufactura de un medicamento para tratar la enfermedad de alzheimer y/o para regular dichos niveles de peptidos amiloides beta en un sujeto
ES2312624T3 (es) * 2001-09-21 2009-03-01 Schering Corporation Metodos para tratar o prevenir la inflamacion vascular usando un inhibidor (inhibidores) de la absorcion de esterol.
JP2005504091A (ja) * 2001-09-21 2005-02-10 シェーリング コーポレイション ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
US20030119808A1 (en) * 2001-09-21 2003-06-26 Schering Corporation Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) * 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
WO2004043457A1 (en) * 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
CA2517571C (en) * 2003-03-07 2011-07-05 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
MXPA05009501A (es) 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
EP1606287B1 (en) * 2003-03-07 2013-10-02 Merck Sharp & Dohme Corp. Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US7459442B2 (en) * 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
WO2005046797A2 (en) * 2003-11-05 2005-05-26 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2170930B3 (en) 2007-06-04 2013-10-02 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
RS65632B1 (sr) 2013-06-05 2024-07-31 Bausch Health Ireland Ltd Ultra-prečišćeni agonisti guanilat-ciklaze c, postupak njihove pripreme i upotrebe

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2826096A1 (de) * 1977-06-17 1979-01-04 Upjohn Co Prostaglandinanaloga
DE2907118A1 (de) * 1979-02-20 1980-09-04 Schering Ag Neue prostacyclin-derivate und verfahren zu ihrer herstellung

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2734791A1 (de) * 1977-07-29 1979-02-15 Schering Ag Neue prostaglandin-i tief 2 -derivate und verfahren zu ihrer herstellung
US4211706A (en) * 1978-10-13 1980-07-08 The Upjohn Company 9-Deoxy-9α,6-nitrilo or 6,9α-imino-17,18-didehydro-PGF compounds
DE2902809A1 (de) * 1979-01-25 1980-08-07 Hoechst Ag Neue analoga von prostacyclin
US4496742A (en) * 1981-10-13 1985-01-29 The Upjohn Company Analogs of 5,6-dihydro PGI2

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2826096A1 (de) * 1977-06-17 1979-01-04 Upjohn Co Prostaglandinanaloga
DE2907118A1 (de) * 1979-02-20 1980-09-04 Schering Ag Neue prostacyclin-derivate und verfahren zu ihrer herstellung

Also Published As

Publication number Publication date
US4446147A (en) 1984-05-01
ATE36152T1 (de) 1988-08-15
IE54097B1 (en) 1989-06-21
EP0059158A2 (de) 1982-09-01
AU8038882A (en) 1982-08-26
IL65055A0 (en) 1982-04-30
EP0059158A3 (en) 1983-03-09
ES509738A0 (es) 1983-02-01
JPS57176960A (en) 1982-10-30
CS228916B2 (en) 1984-05-14
DK72782A (da) 1982-08-21
EP0059158B1 (de) 1988-08-03
ES8301914A1 (es) 1983-02-01
DE3278854D1 (en) 1988-09-08
HU187649B (en) 1986-02-28
IE820355L (en) 1982-08-20
CA1205468A (en) 1986-06-03
JPH0245622B2 (cg-RX-API-DMAC10.html) 1990-10-11
US4567195A (en) 1986-01-28

Similar Documents

Publication Publication Date Title
DE3107100A1 (de) Azaprostacycline, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
EP0055208B1 (de) Neue Carbacycline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CH636354A5 (de) Neue prostaglandin-i(2)-derivate, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel.
DE3306123A1 (de) Neue carbacycline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
CH625797A5 (cg-RX-API-DMAC10.html)
DE3226550A1 (de) Neue carbacycline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
CH636082A5 (de) Prostanderivate, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel.
EP0105288B1 (de) Carbacycline, herstellung und verwendung
DE2719901A1 (de) Pge- und 11-deoxy-pge-verbindungen mit einer methylengruppe am c-9
DE2907118A1 (de) Neue prostacyclin-derivate und verfahren zu ihrer herstellung
EP0086404B1 (de) Neue Carbacycline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE3104044A1 (de) Neue prostacyclin-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
EP0094951B1 (de) Neue prostacycline und verfahren zu ihrer herstellung
DE2606051A1 (de) 2,2-difluor-prostaglandin-e, -f tief alpha, -f tief beta, -a und -b-analoga und verfahren zu deren herstellung
DE3035454A1 (de) 7-oxoprostacyclinderivate und verfahren zu ihrer herstellung
DE2542686A1 (de) 2a,2b-dihomo-15-methyl- und -15- aethyl-pgf-und pge-verbindungen und verfahren zu deren herstellung
DE2830478A1 (de) Prostaglandin-analoge
DE3428266A1 (de) Neue carbacycline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
EP0324815A1 (de) Neue 9-substituierte carbacyclinderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3209702A1 (de) Neue carbacycline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DD233997A5 (de) Verfahren zur herstellung von carbacyclinen
EP0058632B1 (de) (13E)-(8R,11R,12R)-11,15-Dihydroxy-16,19-dimethyl-9-oxo-13,18-prostadiensäuren sowie deren Salze, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
DE2733282A1 (de) Neue prostaglandin-analoga
EP0163672A1 (de) 20-alkyl-7-oxoprostacyclinderivate und verfahren zu ihrer herstellung.
DD210028B3 (de) Verfahren zur herstellung von carbacyclinderivaten

Legal Events

Date Code Title Description
8110 Request for examination paragraph 44
8131 Rejection